Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T Grundström

Second-Site Proviral Enhancer Alterations in Lymphomas Induced by Enhancer Mutants of SL3-3 Murine Leukemia Virus: Negative Effect of Nuclear Factor 1 Binding Site.

Journal of Virology

English

Differential Protein Binding in Lymphocytes to a Sequence in the Enhancer of the Mouse Retrovirus SL3-3.

Molecular and Cellular Biology

Cell Biology

Molecular Biology

1988

English

Related publications

Stability of AML1 (Core) Site Enhancer Mutations in T Lymphomas Induced by Attenuated SL3-3 Murine Leukemia Virus Mutants.

English

Increased Induction of Osteopetrosis, but Unaltered Lymphomagenicity, by Murine Leukemia Virus SL3-3 After Mutation of a Nuclear Factor 1 Site in the Enhancer

English

Increased Lymphomagenicity and Restored Disease Specificity of AML1 Site (Core) Mutant SL3-3 Murine Leukemia Virus by a Second-Site Enhancer Variant Evolved in Vivo.

English

Mutation of All Runx (AML1/Core) Sites in the Enhancer of T-Lymphomagenic SL3-3 Murine Leukemia Virus Unmasks a Significant Potential for Myeloid Leukemia Induction and Favors Enhancer Evolution Toward Induction of Other Disease Patterns

English

Myocyte Enhancer Factor 2 (MEF2)-Binding Site Is Required forGLUT4Gene Expression in Transgenic Mice

Journal of Biological Chemistry

English

The E47 Transcription Factor Binds to the Enhancer Sequences of Recombinant Murine Leukemia Viruses and Influences Enhancer Function.

English

Lymphoid Enhancer Binding Factor-1 (LEF1) Expression as a Prognostic Factor in Adult Acute Promyelocytic Leukemia

Oncotarget

Oncology

2013

English

X-Linked Sideroblastic Anemia Due to ALAS2 Intron 1 Enhancer Element GATA-binding Site Mutations

American Journal of Hematology

Hematology

2014

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T Grundström

Second-Site Proviral Enhancer Alterations in Lymphomas Induced by Enhancer Mutants of SL3-3 Murine Leukemia Virus: Negative Effect of Nuclear Factor 1 Binding Site.

Differential Protein Binding in Lymphocytes to a Sequence in the Enhancer of the Mouse Retrovirus SL3-3.

Related publications

Stability of AML1 (Core) Site Enhancer Mutations in T Lymphomas Induced by Attenuated SL3-3 Murine Leukemia Virus Mutants.

Increased Induction of Osteopetrosis, but Unaltered Lymphomagenicity, by Murine Leukemia Virus SL3-3 After Mutation of a Nuclear Factor 1 Site in the Enhancer

Increased Lymphomagenicity and Restored Disease Specificity of AML1 Site (Core) Mutant SL3-3 Murine Leukemia Virus by a Second-Site Enhancer Variant Evolved in Vivo.

Mutation of All Runx (AML1/Core) Sites in the Enhancer of T-Lymphomagenic SL3-3 Murine Leukemia Virus Unmasks a Significant Potential for Myeloid Leukemia Induction and Favors Enhancer Evolution Toward Induction of Other Disease Patterns

Myocyte Enhancer Factor 2 (MEF2)-Binding Site Is Required forGLUT4Gene Expression in Transgenic Mice

The E47 Transcription Factor Binds to the Enhancer Sequences of Recombinant Murine Leukemia Viruses and Influences Enhancer Function.

Lymphoid Enhancer Binding Factor-1 (LEF1) Expression as a Prognostic Factor in Adult Acute Promyelocytic Leukemia

X-Linked Sideroblastic Anemia Due to ALAS2 Intron 1 Enhancer Element GATA-binding Site Mutations